Ceding Decision-Making to the Most Risk-Averse - 3/16/2026

Investment decisions in drug development require different statistical frameworks than regulatory submissions—applying regulatory standards (multiplicity control, single pre-specified estimands) to staged investment decisions cedes control to the most risk-averse stakeholder and kills promising drugs.

https://www.linkedin.com/posts/brian-smith-67891a5_drugdevelopment-biostatistics-clinicalpharmacology-activity-7439361496905711617-QpTK?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAEGlDwBwD0msjnYupwRjlV-PWIsMwwWd3w